Swedish Orphan Biovitrum expands manufacturing agreement with Amgen
This article was originally published in Scrip
Executive Summary
Swedish Orphan Biovitrum has extended its manufacturing agreement with Amgen to meet an expected increased demand of Kineret (anakinra) until Biovitrum has transferred manufacturing processes to new contract manufacturers.